BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Update

BioLineRx Ltd. (NASDAQ:BLRX) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totalling 827,800 shares, a decrease of 10.2% from the November 30th total of 921,900 shares. Based on an average trading volume of 1,000,000 shares, the days-to-cover ratio is currently 0.8 days.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Atria Investments Inc boosted its stake in shares of BioLineRx by 27.9% during the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 29,193 shares during the period. PVG Asset Management Corp purchased a new stake in shares of BioLineRx during the second quarter worth $70,000. Finally, CVI Holdings LLC purchased a new stake in shares of BioLineRx during the second quarter worth $462,000. Institutional investors and hedge funds own 1.56% of the company’s stock.

Wall Street Analyst Weigh In

BLRX has been the topic of several research analyst reports. StockNews.com assumed coverage on shares of BioLineRx in a research report on Thursday, December 26th. They set a “hold” rating on the stock. HC Wainwright lowered their price target on BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, November 25th.

BioLineRx Stock Up 1.2 %

Shares of BLRX traded up $0.00 during trading hours on Wednesday, reaching $0.21. The company’s stock had a trading volume of 1,393,354 shares, compared to its average volume of 529,682. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. The firm has a market cap of $17.11 million, a price-to-earnings ratio of -0.97 and a beta of 1.39. The company has a 50 day moving average of $0.33 and a two-hundred day moving average of $0.53. BioLineRx has a 1-year low of $0.19 and a 1-year high of $1.59.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.